

DFE Pharma launches Continuous Manufacturing platform to accelerate and enable formulation development

This new CM platform includes cutting-edge equipment, excipients, and expertise in collaboration with Gericke

Goch, Germany - 17th February 2026 - [DFE Pharma](#), a global leader in pharmaceutical excipients, announced the launch of its Continuous Manufacturing (CM) platform, designed to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes. In collaboration with [Gericke](#), a leading international company in high precision feeding, blending, and powder processing equipment, this initiative combines CM-ready excipients, flexible CM evaluation environment, and multidisciplinary expertise, enabling data-driven decisions from early exploration through optimization and long-term operation of CM.

Flexible CM testing environment

As part of the CM platform, DFE Pharma has invested in continuous manufacturing capability at its C2F Center of Excellence in Hyderabad, India, featuring a [Gericke Formulation Skid](#) (GFS). This state-of-the-art formulation skid, with modular feeding and blending options, is placed in a non-GMP environment, enabling fast iterations and practical assessment and optimization without disrupting existing GMP manufacturing or requiring upfront infrastructure investment. The modular setup at the C2F Center supports flexible process and formulations testing by combining the GFS with pre-blending and downstream process and analytical capabilities to generate decision-relevant insights. This equipment gives pharmaceutical companies the opportunity to experience how continuous feeding and blending operate in practice, test formulation strategies using CM-ready materials, and learn how evaluation data translates directly into real world implementation.

CM-ready excipients

DFE Pharma provides a differentiated portfolio of [excipients](#) characterized to perform reliably under continuous processing conditions. These excipients are fit-for-purpose to support stable processing, simplified system design, and robust lifecycle performance, helping pharmaceutical manufacturers manage material variability and meet regulatory expectations throughout development and commercialization.

Applied CM expertise

The CM platform is driven by DFE Pharma's multidisciplinary expertise in formulation development, analytics, process understanding, and variability science, complemented by Gericke's specialized know-how in continuous processing equipment. This combined expertise will support pharmaceutical companies to accelerate learning, reduce uncertainty, and implement robust development and registration strategies aligned with current regulatory expectations, including principles outlined in ICH Q13.

“Continuous Manufacturing is reshaping how medicines are developed and produced, but success depends on making the right choices at every stage,” said **Dr. Sven Abend, Chief Executive Officer at DFE Pharma**. *“With our Continuous Manufacturing platform, we are bringing together our CM-ready excipients, a flexible testing environment, and applied scientific*



expertise. We are sure this platform will enable our customers to make informed, data-driven CM decisions from early exploration through optimization and long-term operation with confidence.”

*“This platform brings together our applied expertise in formulation development, powder handling, and continuous processing science. At Gericke, we contribute decades of engineering and process knowledge, helping customers interpret CM data, understand material–equipment interactions, optimize key parameters, and align their strategies with guidelines such as ICH Q13. Together, we provide clear, science-based direction that supports a smooth transition to robust Continuous Manufacturing,” explained **Markus Gericke, CEO at Gericke Group.***

Continuous manufacturing is a process in which raw materials are continuously fed, transformed through controlled unit operations, and simultaneously discharged as finished product. It enables more consistent product quality, improved process control and the potential for smaller equipment footprints and more efficient use of resources compared to the more commonly used batch manufacturing. Several major pharmaceutical companies have already demonstrated the benefits of CM and integrated continuous processes into parts of their operations. Others are progressing toward CM as well, although adoption can be challenging due to high investment needs, regulatory and operational uncertainties, and the requirement for specialized skills and process understanding.

About DFE Pharma

DFE Pharma is a global leader in pharmaceutical excipient solutions. We develop, produce, and supply high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for oral solid dose (OSD), respiratory, ophthalmic and parenteral formulations.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilizing active ingredients. With more than a century of experience and around 450 people worldwide, we are serving over 5,000 customers in 100+ countries worldwide. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical companies to improve patients’ lives, driven by our purpose: *Your medicines, our solutions. Moving to a healthier world.*

Learn more at www.dfepharma.com or follow us on social media.

About Gericke

The Swiss Gericke Group has been designing and manufacturing equipment and systems for automated bulk material processes, as well as providing design and engineering services, for more than 130 years. Gericke bulk materials processing technology can be found throughout the world in many sectors including the food, chemical, pharmaceutical, plastics and construction material industries.

Gericke’s fully owned group companies employ more than 350 experienced professionals and are located in Switzerland, Germany, Great Britain, The Netherlands, France, USA, Brazil, Singapore, Indonesia, Malaysia, Thailand and China.

Media contacts:

DFE Pharma:

Katja Soto – Global External Communications Manager, DFE Pharma

Email: katja.soto@dfepharma.com, Mobile: + 34 686 582 906

Gericke:

Press contact: Communication, T +41 44 871 36 82, communications.ch@gerickegroup.com

Inquiries: gerickegroup.com, info@gerickegroup.com

Gericke AG, Althardstrasse 120, CH-8105 Regensdorf, T +41 44 871 36 36, F +41 44 871 36 00